"..... would you mind to explain, once more, the importance of the withheld data and how it relates to the overall scheme of things?"

It's the CKD sub-study. We already know from disclosed data that apabetalone elicited amazing 50% MACE reduction in those patients with stage 3 CKD (baseline eGFR<60). We are waiting for the kidney function data (change in eGFR, etc). Big news if apabetalone elicits MACE reduction and improved eGFR in diabetics with CKD.

BDAZ